Cohance Lifesciences Limited is a Hyderabad-based contract development and manufacturing organization (CDMO) that provides services to leading global pharmaceutical and fine chemical companies in their new chemical entity (NCE) development endeavors. The company offers comprehensive solutions ranging from process research and development to late-stage clinical and commercial manufacturing, committed to delivering products that meet customer needs and expectations.
The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. Founded in 1989 and based in Hyderabad, India, Cohance Lifesciences Limited operates as a subsidiary of Berhyanda Limited.
Cohance Lifesciences Limited operates as a technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The company's business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) including formulations.
The company's integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. The company's process research services encompass route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Cohance offers active pharmaceutical ingredients and formulations for various applications, CDMO services providing flexible and custom solutions for challenging development and manufacturing needs, and clinical, analytical, and research services. The company also manufactures finished dosage formulations for pharmaceutical companies and specialty chemicals, such as electronic chemicals.
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is recognized as one of the top 5 providers of high-end intermediates to innovators in India. This positioning reflects the company's expertise in serving the pharmaceutical and chemical industries with specialized manufacturing capabilities.
As of July 10, 2025, Cohance Lifesciences Ltd has a market capitalization of Rs. 38,101.76 crore. The company's market cap stands at 38,228 crore (up 22.7% in 1 year) with revenue of 1,198 crore and profit of 265 crore.
Key financial metrics include:
- Revenue: Rs. 1,198 crore
- Profit: Rs. 265 crore
- TTM profit after tax: Rs. 268 crore
- In FY 2024, the company recorded total revenue of approximately 1,093.51 crore
The stock has a price-to-earnings ratio of 144 and a book value of Rs. 66.6. The latest PE ratio as of July 10, 2025 is 140.82. The company's 52-week high share price is Rs. 1,359.00 and 52-week low share price is Rs. 656.35.
Cohance Lifesciences Ltd has delivered a return of 29.92% in the last 3 years. Over the last 12 months, the share price moved up by 50.54% on BSE, and over the last 3 years, it moved up by 111.38% on BSE.
The promoter holding in the company stands at 66.4%. Promoter holding has increased to 66.41% as of May 2025 from 50.10% as of September 2024. The promoter of Cohance Lifesciences Ltd is Berhyanda Limited, which owns 50.1% of the total equity. The chairman of the company is Vivek Sharma, and the managing director is V Prasada Raju.
The company's Return on Capital Employed (ROCE) averaged 22.3% from the financial year ending March 2023 to 2025, with a median of 19.5%. It peaked at 32.5% in March 2023, reflecting strong capital efficiency over the period. The company maintains a low debt-to-equity ratio of 0.04.
The company trades on both BSE (543064) and NSE (COHANCE). The stock is part of multiple indices including BSE 500, BSE Healthcare, Nifty 500, BSE SmallCap, Nifty MNC, BSE Allcap, BSE SmallCap Select Index, BSE 250 SmallCap Index, BSE 400 MidSmallCap Index, Nifty MidSmallcap 400, Nifty Smallcap 250, and Nifty 500 Multicap 50:25:25.
According to analyst recommendations, Cohance Lifesciences Ltd shares have a "Buy" rating for the long term. The company's future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and -0.1% annually, respectively.
Despite the company reporting repeated profits, it is not currently paying out dividends. The dividend yield stands at 0.00%.
The company continues to strengthen its position in the pharmaceutical contract manufacturing sector, benefiting from the growing trend of outsourcing by global pharmaceutical companies and the increasing demand for specialized chemical synthesis services.
